No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALLR Allarity Therapeutics
- 0.5800
- -0.0299-4.90%
Trading Jun 4 13:41 ET
10.21MMarket Cap0.00P/E (TTM)
0.6100High0.5725Low1.01MVolume0.6025Open0.6099Pre Close592.16KTurnover5.71%Turnover RatioLossP/E (Static)17.61MShares269.800052wk High-1.28P/B10.21MFloat Cap0.550052wk Low--Dividend TTM17.61MShs Float509600.0000Historical High--Div YieldTTM6.15%Amplitude0.5500Historical Low0.5890Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Boston (May 20, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that
Allarity Therapeutics | 10-Q: Quarterly report
Allarity Therapeutics: Strategic Focus Now Solely on Stenoparib >ALLR
Allarity Therapeutics: Strategic Focus Now Solely on Stenoparib >ALLR
Allarity Therapeutics Requested SEC to Withdraw Form S-1 Filed Last Oct >ALLR
Allarity Therapeutics Requested SEC to Withdraw Form S-1 Filed Last Oct >ALLR
Allarity Therapeutics On Track to Regain Compliance With All Nasdaq Listing Requirements >ALLR
Allarity Therapeutics On Track to Regain Compliance With All Nasdaq Listing Requirements >ALLR
Allarity Therapeutics 1Q Loss $3.88M >ALLR
Allarity Therapeutics 1Q Loss $3.88M >ALLR
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg